← boardnext 2027-01-31
CELZ
Creative Medical Technology Holdings Incdistress 7/10 · high distress / dilution risk$0.82-2%today-85% from 52w high
Pain 1
Lead: Type 1 Diabetes · est. market ~$70B (approx, global)
Revenue
pre-revenue
Liquidity
$6M
Runway
1.0 yrs
Shares 1y
+43%
Price & events
-63.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.3%
1D
-4.5%
1W
-58.3%
1M
-63.3%
3M
-60.9%
6M
-70.3%
1Y
-76.9%
2Y
-99.5%
5Y
-99.5%
All
Overview
- Market Cap
- $3.04M
- Volume
- 29.03K
- 52 Week Range
- $0.81 – $5.59
- Total Shares
- 3.70M
- Float Shares
- 3.43M
- Short %
- 9.36%
- % Held by Insiders
- 0.95%
- % Held by Institutions
- 6.50%
- RVOL
- 0.00x
- Beta
- 1.88
Pipeline stages · 1 programs
CELZ-201 Administration
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01-31 Estimated 50% readout ~2027-03-17 | Phase 1/2 | CELZ-201 Administration | Type 1 Diabetes, Diabetes Mellitus, Type 1 | — | recruiting |
| 2026-05-01 | Phase 1/2 | CELZ-201-DDT | Chronic Low-back Pain, Degenerative Disc Disease | 45 | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $20 (+2334% upside) · 1 analysts
- no recent rating changes
Competitors — Type 1 Diabetes
- LLYELI LILLY & Co$1094.4B · D3
- VRTXVERTEX PHARMACEUTICALS INC / MA$119.1B · D1
- SNYSanofi$52.5B · D1
- NKTRNEKTAR THERAPEUTICS$2.3B · D8
- IMCRImmunocore Holdings plc$1.8B · D1
- MNKDMANNKIND CORP$1.2B · D0
- SANASana Biotechnology, Inc.$860M · D7
- IPSCCentury Therapeutics, Inc.$381M · D6
- SABSSAB Biotherapeutics, Inc.$270M · D3
- BMEABiomea Fusion, Inc.$90M · D6
Recent news
- 2026-07-14Creative Medical Technology Holdings Inc. (CELZ) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
- 2026-07-13Creative Medical Technology (CELZ) Slides 3% as Stock Tests Key Support Level - Dividend Arbitrage - dars.gov.et
- 2026-07-02Creative Medical Technology Raises $4.5M From Warrant Exercises, Reprices and Issues New 5-Year Warrants - TradingView
- 2026-07-02Creative Medical Technology awards $100,000 bonus to CEO Timothy Warbington - TradingView
- 2026-07-01Creative Medical (CELZ) asks shareholders to OK 5.58M warrants, 100M cap increase - Stock Titan
- 2026-07-01Creative Medical provides mid-year business update By Investing.com - Investing.com South Africa
- 2026-07-01Creative Medical Technology Holdings Issues Mid-Year Update - marketscreener.com
- 2026-07-01Creative Medical Technology Holdings Issues Mid-Year Update - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.